Pamela Lukasewicz Ferreira, PhD, University of Pittsburgh, Pittsburgh, PA, explores the current diagnostic and prognostic value of blood-based biomarkers in Alzheimer’s disease research and practice. As an alternative to traditional PET assessment, blood-based biomarker detection has potential to provide a time-efficient, cost-effective strategy for pre-screening and treatment monitoring in Alzheimer’s disease (AD) clinical trials. Although the widespread use of blood-based biomarkers in clinical practice remains to be seen, they hold promise in expediting diagnostic/prognostic procedures for AD. Dr Lukasewicz Ferreira notes that thresholds must be defined, to reliably differentiate AD patients from healthy individuals. Employing a standardized approach to measure blood-based biomarkers may allow for successful translation to clinical practice. This interview took place at the AD/PD™ 2024 congress in Lisbon, Portugal.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
